Overview: Lyme Disease IgG Immunoblot TestIntroduction: The Lyme Disease IgG Immunoblot Test detects Borrelia IgG to diagnose chronic Lyme disease, causing joint pain or fatigue. Following 2023 IDSA guidelines, it uses immunoassay for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected chronic Lyme disease.
Other Names: Lyme IgG Assay, Chronic Lyme Immunoblot Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Lyme IgG testing emerged in the 1980s with Lyme disease research. Immunoblot methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Borrelia IgG to diagnose chronic Lyme disease, guides treatment, and evaluates patients with joint pain or fatigue.
Test Parameters: 1. Borrelia IgG Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of joint pain, fatigue, or tick exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document joint pain, fatigue, neurological symptoms, or history of tick exposure. Include current medications, especially antibiotics.
Consent: Written consent required, detailing the tests purpose, Lyme disease implications, and risks of blood or saliva collection.
Procedural Considerations: Uses immunoassay (immunoblot) to detect Borrelia IgG in serum or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for chronic Lyme disease diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Early infection may yield false negatives.
Clinical Significance: Positive IgG confirms chronic Lyme disease, guiding extended antibiotic therapy. Negative results may require further testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: Lyme PCR, IgM immunoblot, or Western blot to confirm Lyme disease diagnosis.
Test Limitations: May detect past exposure; clinical correlation is needed. Cross-reactivity with other spirochetes may occur.
References: IDSA Lyme Disease Guidelines, 2023; Clinical Infectious Diseases, Wormser GP, 2022.
